Antibe Therapeutics Inc.
ATBPF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | 0.5% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | 36.5% | 38.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -236.9% | -186% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -270.8% | -200.1% |
| EPS Diluted | -0.37 | -0.49 | -0.7 | -0.71 |
| % Growth | 24.5% | 30% | 1.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |